Corona virus vaccine: when will it be ready?

          Even their most effective - and rigorous - prevention strategies have only slowed down the spread of respiratory disease Covid-19. With the World Health Organization finally declaring an epidemic, all eyes have turned to the possibility of a vaccine, because only one vaccine can prevent people from getting sick.

Live update corona case click here

          About 35 companies and academic institutions are racing to create such a vaccine, of which at least four are already candidates, of which they are testing in animals. The first of these - formed by Boston-based biotech firm latest - will enter human trials imminently.

          This record momentum is in great part thanks to early Chinese efforts to order the genetic material of Saras-CoV-2, the virus that causes Covid-19. China shared that sequence in early January, allowing research groups around the world to develop the Zika virus and study how it attacks human cells and makes people sick. But there is additional reason for the head to start. Although no one could have predicted that the next infectious disease would threaten the world caused by a coronavirus — flu is generally believed to pose the greatest pandemic risk — vaccinologistsn "Prototype" Was hedging his bets by working on pathogens.

          Richard Haschett, CEO of the Oslo-based non-profit. The Coalition for Epidemic Preparedness, says's "The speed at which we [produced these candidates] makes it very much on investment in understanding Novelty (CEPI), which is leading efforts to investment and coordinate covid-19 vaccine development. Coronavirus has recently caused two other epidemics -- severe acute respiratory syndrome (SARS) in China in 2002-04, and Middle East Respiratory Syndrome (MERS), which began in Saudi Arabia in 2012. In both cases, work began on vaccines that were later removed upon spread.

           One company, Maryland-based Novavax, has now repurposed those vaccines for The SARS-CoV-2, and says it's ready to let several candidates enter human trials this spring. Meanwhile, the US National Institute of Allergy and Infectious Diseases built on earlier work on the MERS virus in Bethesda, Maryland.

          SARS-CoV-2 shares between 80% and 90% of its genetic solid with viruses that cause SARS – hence its name. Both have a strip of ribonucleic acid (RNA) exclusive a spherical protein capsule that is covered in spikes. Spikes lock the human lungs on to receptors on the surface of lining cells - the same type of receptor in both cases - allowing the virus to break Once inside, it hijacked the cell's breeding machinery to produce more copies of itself, before breaking out of the cell again and killing it in the process.

          All vaccines work rendering to the same basic principle. They are current all part or all of the pathogen to the human immune system, typically in the form of an injection and at low doses, to prompt the Traditionally, vaccination has been achieved using live, weak forms of the virus, or part or whole of the virus once it has been inactive by heat or chemicals.

          The live form can continue to develop into hosts, for example, potentially recapturing some of its severity and making the recipient sick, while high or repeating doses of inactive viruses are necessary to obtain the necessary amount of protection. Some of the Covid-19 vaccine projects are using these tried and tested approaches, but others are using the new technology. Another recent strategy - which is using Novavox, for example - is a 1,000,000,000,000 "Recombination0 Manufactures vaccines. This includes confiscating genetic code for protein spikes on the surface of SARS-COV-2, which is part of a virus most likely to provoke an immune reply in humans, and pasting it into the genome of bacteria or yeast - forcing these microorganisms to churn out Exclude large amounts of protein. Other approaches, even new, bypass proteins and build vaccines only from genetic instruction. This is the case for Moderna and extra Boston company, CureVac, both of which are structure Covid-19 vaccines out of Messenger RNA. Cepi's original portfolio of four funded Covid-19 vaccine plans was heavily skewed towards these more innovative technologies, and last week it announced capital of the $4.4m (£3.4m) partnership with Novavax and the Oxford Project with a University of The Vaictored Vaccine . clinical or human testing, which, for some candidates, is going to get in the way.

          The problem is making sure that the vaccine is available to all those who need it. This is also a challenge within the countries, and some have drawn up guidelines. In the scenario of a flu pandemic, for example, britain will prioritise vaccinating health care and social care workers, as well as considering the highest medical risks - including children and pregnant women - with the overall goal of keeping illness and death rag as much as possible As low as te. But in the epidemic, countries also have to compete with each other for medicines. Because epidemics tend to hardest hit those countries that have the most fragile and underfunded health systems, there is an inherent imbalance between the needs and purchasing power when it During the 2009 H1N1 flu pandemic, for example, vaccine supplies were broken down by nations that could afford them, leaving poor people less. But you can also imagine a scenario where India – a major supplier of vaccines to the developing world – does not decide to improperly use its vaccine production to protect its 1.3 billion-strong population before any exports.